Form 8-K - Current report:
SEC Accession No. 0000950170-25-071357
Filing Date
2025-05-14
Accepted
2025-05-14 16:04:33
Documents
13
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K maze-20250514.htm   iXBRL 8-K 46108
2 EX-99.1 maze-ex99_1.htm EX-99.1 92964
3 GRAPHIC img92905542_0.jpg GRAPHIC 11656
  Complete submission text file 0000950170-25-071357.txt   277659

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT maze-20250514.xsd EX-101.SCH 24819
15 EXTRACTED XBRL INSTANCE DOCUMENT maze-20250514_htm.xml XML 4727
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Filer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42490 | Film No.: 25945230
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)